Skip to content
Review Open access

Non-pharmacological strategies for the management of Alzheimer's disease

Aug 2026 · Dementia & Neuropsychologia · Vol 20 · 0 citations · 97 references
Medicine

TL;DR

The evidence on diverse non-pharmacological therapies for managing AD is synthesized and their practical implications for clinical care are discussed to generate a broader and more lasting impact on disease treatment.

Abstract

Abstract Alzheimer's disease (AD) is a multifactorial neurodegenerative disease affecting various cognitive domains, requiring a holistic and integrated therapeutic approach. The treatment of AD goes beyond pharmacological interventions, also necessitating non-pharmacological therapies that can act synergistically, both with each other and with emerging pharmacological treatments, including new anti-amyloid therapies. These therapies aim to improve patients’ quality of life and alleviate behavioral symptoms, such as agitation and depression, and delay disease progression. Current clinical and meta-analytic evidence suggests that these approaches can be effectively integrated with conventional treatment, offering a valuable alternative to enhance patients’ overall well-being. However, further research is needed to deepen the understanding of the ideal combination of the new anti-amyloid therapies, to address the limitations of current evidence, and to robustly establish their effectiveness in the clinical context of AD, aiming to generate a broader and more lasting impact on disease treatment. This narrative review aims to synthesize the evidence on diverse non-pharmacological therapies for managing AD and discuss their practical implications for clinical care.

Read PDF

Similar papers

Review Open access Jul 2026

Advancements in non-pharmaceutical interventions for Alzheimer’s disease management: an update review

This review systematically synthesizes literature from the PubMed and Web of Science databases to evaluate the comparative efficacy of physical activity, dietary interventions, and cognitive stimulation therapy (CST), aiming to establish an evidence-based framework for optimized clinical implementation.

Jialin Chen, Ziyu Zhang · 0 citations
Review Aug 2026

Neuropharmacological Interventions in Alzheimer’s Disease: Current and Emerging Approaches

Alzheimer’s Disease (AD) is a neurodegenerative disorder with progressive cognitive decline, β-amyloid plaques, neurofibrillary tangles, oxidative stress, and neuroinflammatory responses. So far, the pathogenesis of AD has been explained by the cholinergic hypothesis, amyloid cascade hypothesis, and tau protein dys...

Lalit Parihar, A. Singh, Sanjar Alam · 0 citations
Review Sep 2026

Investigating oral blarcamesine for treatment of early Alzheimer's disease.

INTRODUCTION Alzheimer's disease (AD) is the most common neurodegenerative dementia affecting millions globally. Therapies primarily consist of symptomatic management and progression limitation. Further advances in treatments include disease-modifying therapies, many of which have unfavorable safety profiles and modest...

Abarajithan Chandrasekaran, Alexandra Paget-Blanc, Boris Decourt et al. · 0 citations
Review Open access Aug 2026

THERAPY FOR ALZHEIMER’S DISEASE - FOCUS ON LECANEMAB

Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder and the leading cause of dementia worldwide, with prevalence increasing due to population aging. It is characterized by cognitive decline, functional impairment, and significant public health burden. Pathophysiology involves a complex interpl...

Mikołaj Jońca, Gabriela Majchrowicz, Natasza Kurys et al. · 0 citations
Review Open access Jul 2026

Mechanisms and Intervention Strategies of Beta-Amyloid and Tau Proteins in Alzheimer's Disease

The synergistic pathological network between Aβ and tau is clarified, updated progress on targeted therapies are summarized, and theoretical support for accurate early diagnosis and individualized clinical treatment of AD is offered.

Kexin Liu · 0 citations
Review Open access Aug 2026

NEW THERAPEUTIC OPPORTUNITIES IN ALZHEIMER'S DISEASE: THE ROLE OF ANTI-AMYLOID ANTIBODIES: A COMPREHENSIVE REVIEW

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, neuronal loss, and the accumulation of β-amyloid plaques and tau pathology. For many years, pharmacological treatment has been limited to symptomatic therapies, including acetylcholinesterase inhibitors and memantin...

Kacper Jaskulski, Katarzyna Kowalenko, J. Szadkowski et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.